Buparlisib

Buparlisib Market Outlook

The global Buparlisib market is projected to reach approximately USD 1.8 billion by 2035, growing at a robust compound annual growth rate (CAGR) of about 7.2% during the forecast period of 2025 to 2035. This growth is primarily driven by the increasing prevalence of various cancers, which necessitates innovative treatment options like Buparlisib, a selective PI3K inhibitor. Alongside the rising rates of cancer and neurological disorders, advancements in pharmaceutical research and development are expected to play a pivotal role in expanding the market. Furthermore, the rise in healthcare expenditure and improved access to therapies across emerging economies are also contributing factors to the market's anticipated growth. The increasing awareness and adoption of targeted therapies are expected to drive significant investments in the Buparlisib market as a part of personalized medicine strategies.

Growth Factor of the Market

The Buparlisib market is experiencing growth due to several key factors that are driving its demand within the healthcare industry. One of the primary drivers is the increasing incidence of cancers, especially breast cancer, as well as other diseases that require effective treatment options. Moreover, the rising geriatric population, which is more susceptible to chronic diseases, contributes further to market growth. Another noteworthy factor is the ongoing clinical trials and research initiatives aimed at enhancing the efficacy and safety of Buparlisib in treating various conditions, which is expected to bolster its market presence substantially. Additionally, the growing trend towards personalized medicine, which tailors treatment based on individual patient needs, is creating a favorable environment for Buparlisib's adoption. As healthcare systems worldwide focus on improving patient outcomes and optimizing treatment protocols, the importance of innovative therapies like Buparlisib continues to rise.

Key Highlights of the Market

• The global Buparlisib market is projected to reach USD 1.8 billion by 2035.
• The market is expected to grow at a CAGR of 7.2% from 2025 to 2035.
• Increasing incidence of cancers and neurological disorders drives demand.
• Ongoing research and development enhance market opportunities.
• Rising awareness about targeted therapies boosts market adoption.

By Product Type

Tablet:

Tablets represent a significant segment within the Buparlisib market, primarily due to their convenience and ease of administration. This form of Buparlisib is favored by both healthcare professionals and patients alike. Tablets are typically associated with better adherence to treatment regimens, which is crucial for managing chronic conditions like cancer. Furthermore, advancements in tablet formulation, including controlled-release technologies, have enhanced the effectiveness of Buparlisib when administered in this form. The accessibility of tablets in various healthcare settings, from hospitals to retail pharmacies, contributes positively to their market share, allowing for widespread distribution and patient compliance.

Capsule:

Capsules are another popular product type in the Buparlisib market due to their benefits over traditional tablet formulations. Capsules are often easier to swallow and can mask the taste of the active ingredients, making them a more palatable option for patients. Moreover, capsules allow for the incorporation of liquid formulations, which can improve bioavailability and absorption rates of Buparlisib. The flexibility of capsule manufacturing enables pharmaceutical companies to innovate with formulations, including extended-release versions, which prolong therapeutic effects. This versatility in dosage forms is anticipated to drive the growth of the capsule segment within the Buparlisib market.

Injection:

The injection segment of the Buparlisib market is gaining traction, particularly in clinical settings where rapid action is required. Injectables provide the advantage of direct delivery into the bloodstream, ensuring immediate therapeutic effects, which is critical in cancer treatment scenarios. Additionally, injectable forms of Buparlisib are often used in combination with other treatments to enhance efficacy. The development of pre-filled syringes and auto-injectors has further facilitated ease of use, catering to both healthcare providers and patients. This segment is expected to grow significantly as healthcare professionals increasingly adopt injectable therapies for more aggressive treatment protocols.

Liquid:

Liquid formulations of Buparlisib are becoming an essential component of the market, particularly for patients who have difficulty swallowing solid forms of medication. Liquid Buparlisib allows for flexible dosing and can be tailored to meet individual patient needs, making it particularly suitable for pediatric and geriatric populations. The development and improvement of liquid formulations have increased the absorption rates, which can potentially lead to better patient outcomes. As healthcare providers and patients seek more adaptable medication options, the liquid segment of the Buparlisib market is poised for growth.

Others:

This category encompasses various alternative formulations and delivery methods of Buparlisib not classified under the primary forms. These could include novel formulations under investigation that integrate Buparlisib into complex biological products or novel drug delivery systems. As pharmaceutical innovation progresses, there is potential for new product types to enter the market, which could meet specific patient needs or enhance the pharmacological profile of Buparlisib. The 'Others' segment reflects the dynamic nature of pharmaceutical research and development, where emerging technologies might reshape treatment options in the future.

By Application

Oncology:

Oncology is the leading application segment for Buparlisib, driven by the increasing incidence of various cancers worldwide. Buparlisib, as a PI3K inhibitor, has demonstrated substantial efficacy in clinical trials for treating solid tumors, particularly breast cancer. This has resulted in a heightened focus on oncology applications, with ongoing studies further exploring its potential in combination therapies. As research continues to unfold and more patients are diagnosed with cancer, the demand for effective treatments like Buparlisib is expected to continue increasing, solidifying its position in the oncology market.

Neurology:

The neurology application for Buparlisib is gaining ground as research expands into its effects on neurological disorders. With the rising prevalence of neurodegenerative diseases such as Alzheimer's and Parkinson's, there is a growing need for innovative therapeutic options. Preliminary studies indicate that Buparlisib may provide neuroprotective effects, making it a candidate for treating such conditions. As awareness and understanding of the underlying mechanisms of these diseases grow, the potential for Buparlisib in neurological applications is anticipated to develop, offering new hope for patients and healthcare providers alike.

Cardiology:

The cardiology application segment of the Buparlisib market is emerging, particularly in relation to its effects on cardiovascular diseases. With the increasing global burden of heart-related ailments, there is a significant push towards finding effective treatments. Some research indicates that Buparlisib may play a role in modulating metabolic pathways that impact cardiac function. As this area of research matures, there may be opportunities to leverage Buparlisib in cardiology, thereby expanding its clinical utility and market presence.

Rheumatology:

The rheumatology segment is increasingly recognized as a potential application area for Buparlisib, especially in treating autoimmune and inflammatory conditions. Conditions such as rheumatoid arthritis may benefit from the PI3K pathway modulation that Buparlisib offers. The growing emphasis on immunotherapy in rheumatology could position Buparlisib favorably as a treatment option. As clinical trials progress and more data becomes available, Buparlisib may carve out a significant role in addressing unmet needs within the rheumatological landscape.

Others:

This segment caters to various other applications of Buparlisib that do not fall under the primary categories like oncology, neurology, cardiology, or rheumatology. Ongoing research may identify alternative therapeutic areas for Buparlisib, potentially expanding its utilization. For instance, applications in metabolic disorders or infectious diseases are being explored, which could lead to innovative treatment strategies. As researchers investigate new avenues for Buparlisib, this segment reflects the dynamic and evolving nature of pharmaceutical applications.

By Distribution Channel

Hospitals:

Hospitals are a critical distribution channel for Buparlisib, as they are often the primary setting for cancer treatment and other serious health conditions. Within hospitals, Buparlisib is typically administered under the supervision of healthcare professionals, ensuring that patients receive appropriate care and monitoring. The presence of specialized oncology departments enhances the accessibility of Buparlisib, contributing to its growth within this channel. As hospitals continue to expand their oncology programs and integrate new therapies, the role of Buparlisib in hospital settings is expected to increase significantly.

Retail Pharmacies:

Retail pharmacies play an essential role in the Buparlisib market by providing patients with access to this crucial medication outside of hospital settings. The convenience of retail pharmacies allows for easy refills and consultations, making it a popular choice among patients. Moreover, retail pharmacies often engage in patient education initiatives, which can increase awareness about Buparlisib and its benefits. As the demand for outpatient treatment options grows, retail pharmacies are likely to expand their offerings, including Buparlisib, to cater to patients’ needs.

Online Pharmacies:

The online pharmacy segment is rapidly gaining prominence in the Buparlisib market, driven by the increasing trend of digital health solutions and e-commerce in pharmaceuticals. Patients appreciate the convenience of ordering their medications online from the comfort of their homes. Online pharmacies often offer competitive pricing and home delivery services, making Buparlisib more accessible to a broader audience. The surge of telehealth services also aligns with the rise of online pharmacies, further enhancing their role in distributing Buparlisib to patients who may prefer remote consultations and purchases.

Specialty Clinics:

Specialty clinics, particularly those focused on oncology and chronic disease management, serve as crucial distribution channels for Buparlisib. These clinics are equipped with specialized staff and resources to administer complex therapies, ensuring that patients receive expert care. The personalized approach offered by specialty clinics allows for tailored treatment plans, enhancing the overall patient experience. As the healthcare landscape evolves and patients seek more specialized care, the reliance on specialty clinics for Buparlisib is expected to grow, solidifying their position in the distribution network.

Others:

This category encompasses various other distribution channels that facilitate access to Buparlisib, including wholesalers and direct-to-consumer models. Wholesalers play a critical role in ensuring the efficient supply chain of Buparlisib to various healthcare providers, while innovative distribution strategies may emerge to reach underserved populations. The 'Others' segment reflects the diversity in distribution methods that are essential for making Buparlisib widely available, ultimately improving patient access to this vital therapy.

By Ingredient Type

Buparlisib Monotherapy:

Buparlisib monotherapy represents a key ingredient type within the market, particularly in oncology applications. As a standalone treatment, Buparlisib has shown considerable efficacy in targeting the PI3K pathway, which is critical in the proliferation of cancer cells. Clinical studies supporting its use as monotherapy have resulted in promising outcomes, thus increasing its appeal among healthcare providers. The focus on monotherapy is likely to persist as researchers continue to explore its effectiveness across various cancer types, thereby solidifying its place in treatment protocols.

Buparlisib Combination Therapy:

Combination therapy involving Buparlisib is gaining traction, particularly in oncology, where the integration of multiple therapeutic agents can enhance treatment outcomes. Studies have shown that combining Buparlisib with other targeted therapies or traditional chemotherapy can significantly improve efficacy and reduce resistance to treatment. This synergistic approach is being actively researched, with clinical trials focusing on optimizing combinations tailored to individual patient profiles. As combination therapies continue to evolve, Buparlisib's role in enhancing treatment regimens is expected to grow, attracting attention from both providers and patients.

Buparlisib Biosimilar:

The introduction of Buparlisib biosimilars is an emerging trend within the market, providing a more cost-effective alternative to the original formulation. As patents for the original Buparlisib product expire, biosimilars can increase market competition and accessibility for patients, particularly in regions with high healthcare costs. The development of high-quality biosimilars is closely monitored by regulatory agencies to ensure that they meet stringent safety and efficacy standards. This segment represents a significant opportunity for pharmaceutical companies as they aim to capture market share and meet the needs of cost-sensitive patients.

Buparlisib Generic:

Buparlisib generics are poised to impact the market significantly as the demand for affordable treatment options grows. Generic formulations of Buparlisib, once approved, can provide cost savings for healthcare systems and patients alike. The availability of generics is expected to increase patient access to this critical therapy, particularly in low- and middle-income countries. As awareness of Buparlisib's efficacy spreads, the generic segment is likely to expand, helping to alleviate financial burdens associated with cancer treatment.

Others:

The 'Others' ingredient type segment captures various formulations and innovative derivatives of Buparlisib that do not fall under the primary categories. This could include research into novel formulations that enhance bioavailability or delivery mechanisms that improve patient outcomes. As pharmaceutical research continues to advance, the 'Others' segment reflects the dynamic nature of drug development, with potential breakthroughs capable of reshaping the Buparlisib landscape.

By Region

The North American region holds a dominant position in the global Buparlisib market, estimated to account for over 40% of the total market share. This robust presence can be attributed to advanced healthcare infrastructure, significant investments in research and development, and a strong emphasis on innovation in pharmaceutical therapies. The rising prevalence of cancer and neurological disorders within the region further fuels market growth, as healthcare providers increasingly adopt targeted therapies like Buparlisib. Additionally, the region is anticipated to witness a CAGR of 7.5% from 2025 to 2035, driven by ongoing clinical trials and an increasing focus on personalized medicine.

In Europe, the Buparlisib market is also expanding, with an estimated market share of around 25%. Factors contributing to this growth include increasing healthcare expenditure, a growing geriatric population, and a strong regulatory framework that encourages the introduction of innovative therapies. The prevalence of chronic diseases in Europe necessitates effective treatment options, positioning Buparlisib as an essential component of therapeutic regimens. Furthermore, the Asia Pacific region is emerging as a significant player in the Buparlisib market, projected to achieve a CAGR of 8.0% due to rising healthcare investments and increasing patient awareness regarding targeted therapies. As the demand for effective cancer treatments expands globally, the Buparlisib market is expected to flourish across all regions.

Opportunities

The Buparlisib market is ripe with opportunities, particularly in the realm of clinical research and development. As pharmaceutical companies continue to invest in novel formulations and combination therapies, there is considerable potential to enhance the therapeutic efficacy of Buparlisib. Ongoing clinical trials exploring its use in various cancer types, including rare forms, can unlock new markets and patient populations, thereby increasing the overall demand for Buparlisib. Additionally, the expansion of healthcare infrastructure in emerging markets presents a unique opportunity for manufacturers to penetrate these regions with their products. As access to healthcare improves, the demand for innovative therapies like Buparlisib is expected to rise, leading to further growth in the market.

Moreover, the growing trend towards personalized medicine creates significant opportunities for Buparlisib. As healthcare providers increasingly seek therapies tailored to individual patient's genetic profiles, Buparlisib's targeted action against specific pathways positions it favorably in this evolving healthcare landscape. The potential for Buparlisib to be included in combination therapies further enhances its attractiveness, as it may work synergistically with other treatments to improve efficacy and reduce side effects. As the focus on personalized treatment strategies intensifies, there is a strong likelihood that Buparlisib will gain recognition as a cornerstone of targeted therapy protocols.

Threats

Despite the promising outlook for the Buparlisib market, there are several threats that could impact its growth trajectory. One of the primary concerns is the intense competition from both existing therapies and emerging treatments that may offer similar or enhanced efficacy. As the pharmaceutical industry becomes increasingly saturated with cancer therapies, the potential for market share dilution grows. Additionally, the emergence of generics and biosimilars can significantly affect the pricing landscape, leading to reduced profit margins for original manufacturers. Companies must continuously innovate to keep pace with competition and maintain their market position, which can pose financial and operational challenges.

Another threat facing the Buparlisib market is the regulatory landscape, which can be unpredictable and subject to change. Stricter regulations regarding drug approvals and post-market surveillance may create barriers to entry for new formulations or therapies. Furthermore, the ongoing scrutiny over drug pricing and reimbursement policies can affect market dynamics, particularly in regions with stringent healthcare regulations. Pharmaceutical companies must navigate these challenges effectively to ensure that Buparlisib remains accessible and viable in an evolving healthcare environment.

Competitor Outlook

• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb
• Amgen Inc.
• Pfizer Inc.
• Roche Holding AG
• AstraZeneca PLC
• Gilead Sciences, Inc.
• Sanofi S.A.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Celgene Corporation
• Incyte Corporation
• Regeneron Pharmaceuticals, Inc.
• Vertex Pharmaceuticals Incorporated

The overall competitive landscape of the Buparlisib market is characterized by the presence of several key players who are committed to research and development initiatives aimed at enhancing treatment efficacy and patient outcomes. Established pharmaceutical companies dominate this market due to their extensive resources, research capabilities, and established distribution networks. These companies are continuously looking to innovate and adapt their strategies to maintain competitive advantages. Collaborations and partnerships with research institutions and other pharmaceutical firms are becoming increasingly common as companies seek to enhance their product portfolios and leverage complementary expertise. Furthermore, the emphasis on personalized medicine is compelling competitors to focus on targeted therapies, which aligns with Buparlisib's profile as a selective PI3K inhibitor.

Major companies such as Novartis AG and Merck & Co., Inc. have made significant strides in developing and marketing Buparlisib, investing heavily in clinical trials to validate its efficacy across various applications. These companies are also exploring combination therapies that leverage Buparlisib alongside other treatment modalities to enhance overall patient outcomes. Their strong presence in the oncology space and commitment to innovation position them favorably within the Buparlisib market. Additionally, companies like Pfizer Inc. and Bristol-Myers Squibb are also investing in research to explore the full therapeutic potential of Buparlisib, which could lead to the development of new treatment protocols and combinations tailored to specific patient needs.

As the Buparlisib market continues to evolve, companies are likely to face new challenges and opportunities. The emergence of biosimilars and generics will require established players to adapt their strategies, focusing on differentiation and value-based offerings. Companies like Amgen Inc. and Gilead Sciences, Inc. are well-positioned to navigate this competitive landscape, leveraging their expertise in oncology and immunotherapy. Additionally, with the ongoing advancements in drug delivery systems and formulation technologies, companies that can successfully innovate in these areas may gain a competitive edge. Overall, the Buparlisib market is poised for continued growth, driven by innovation, collaboration, and a focus on improving patient outcomes.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Amgen Inc.
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Novartis AG
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Sanofi S.A.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 AstraZeneca PLC
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 Roche Holding AG
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Merck & Co., Inc.
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Incyte Corporation
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Celgene Corporation
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Bristol-Myers Squibb
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Gilead Sciences, Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Regeneron Pharmaceuticals, Inc.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Teva Pharmaceutical Industries Ltd.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Vertex Pharmaceuticals Incorporated
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Buparlisib Market, By Application
    • 6.1.1 Oncology
    • 6.1.2 Neurology
    • 6.1.3 Cardiology
    • 6.1.4 Rheumatology
    • 6.1.5 Others
  • 6.2 Buparlisib Market, By Product Type
    • 6.2.1 Tablet
    • 6.2.2 Capsule
    • 6.2.3 Injection
    • 6.2.4 Liquid
    • 6.2.5 Others
  • 6.3 Buparlisib Market, By Ingredient Type
    • 6.3.1 Buparlisib Monotherapy
    • 6.3.2 Buparlisib Combination Therapy
    • 6.3.3 Buparlisib Biosimilar
    • 6.3.4 Buparlisib Generic
    • 6.3.5 Others
  • 6.4 Buparlisib Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Retail Pharmacies
    • 6.4.3 Online Pharmacies
    • 6.4.4 Specialty Clinics
    • 6.4.5 Others

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Buparlisib Market by Region
  • 10.3 Asia Pacific - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 India
      • 10.3.1.2 China
      • 10.3.1.3 Japan
      • 10.3.1.4 South Korea
  • 10.4 Latin America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 Brazil
      • 10.4.1.2 Argentina
      • 10.4.1.3 Mexico
  • 10.5 North America - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 USA
      • 10.5.1.2 Canada
  • 10.6 Middle East & Africa - Market Analysis
    • 10.6.1 By Country
      • 10.6.1.1 Middle East
      • 10.6.1.2 Africa

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Buparlisib market is categorized based on

By Product Type

• Tablet
• Capsule
• Injection
• Liquid
• Others

By Application

• Oncology
• Neurology
• Cardiology
• Rheumatology
• Others

By Distribution Channel

• Hospitals
• Retail Pharmacies
• Online Pharmacies
• Specialty Clinics
• Others

By Ingredient Type

• Buparlisib Monotherapy
• Buparlisib Combination Therapy
• Buparlisib Biosimilar
• Buparlisib Generic
• Others

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Novartis AG
• Merck & Co., Inc.
• Bristol-Myers Squibb
• Amgen Inc.
• Pfizer Inc.
• Roche Holding AG
• AstraZeneca PLC
• Gilead Sciences, Inc.
• Sanofi S.A.
• AbbVie Inc.
• Teva Pharmaceutical Industries Ltd.
• Celgene Corporation
• Incyte Corporation
• Regeneron Pharmaceuticals, Inc.
• Vertex Pharmaceuticals Incorporated